Home | Contact | Directions
Bookmark and Share

Newsroom

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

Posted in Constellation in the News, Newsroom

Our paper “EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation” is now available in Cell Press, Chemistry and Biology.

View full paper here

Read more »

Constellation meets contractual milestones and receives balance of $15 million loan

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has secured a $15 million senior secured loan with Oxford Finance and Silicon Valley Bank.  Constellation had already drawn down $5 million from this facility, which was originally closed back in June of 2013 and,

Read more »

Constellation Expands Clinical Studies of CPI-0610

Posted in Constellation in the News, Newsroom

Today, Constellation announced that it has initiated two additional clinical studies of its lead BET Inhibitor, CPI-0610.  CPI-0610 has been progressing in a Phase 1 clinical trial in patients with lymphoma since September of 2013.  As that trial continues, two …

Read more »

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

Posted in Constellation in the News, Newsroom

In this paper just published in PNAS, Dr. Lou Staudt and his colleagues at the United States National Cancer Institute and scientists from Constellation Pharmaceuticals demonstrated that combination of the recently approved drug, ibrutinib, with small molecule BET bromodomain inhibitors …

Read more »

Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

Posted in Constellation in the News, Newsroom

At this year’s AACR Annual Meeting Constellation will be represented by one oral presentation and four posters encompassing work on chromatin biology.

Patrick Trojer will be giving a talk entitled “Targeting Histone Lysine Methylation in Cancer”, in Saturday's 11:45 am …

Read more »

Constellation Pharmaceuticals named one of The Boston Globe’s Top Places to Work 2013

Posted in Constellation in the News, Newsroom

For more information including the full article as well as the list of other employers recognized for this honor click herewww.bostonglobe.com/topplaces.…

Read more »

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Posted in Constellation in the News, Newsroom

Our paper "Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth’ is now available in Cell Press, Chemistry & Biology.

View full paper here. …

Read more »

Constellation Pharmaceuticals and the University of Pittsburgh School of Medicine Receive Cystic Fibrosis Foundation Research Grant

Posted in Constellation in the News, Newsroom

 CAMBRIDGE, Mass. – October 10, 2013Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of …

Read more »

BET bromodomain inhibition suppresses Th17-mediated pathology

Posted in Constellation in the News, Newsroom

http://www.constellationpharma.com/wp-content/uploads/J-Exp-Med-2013-Mele-jem-201303761.pdfConstellation Pharmaceuticals Announces New Preclinical Data on Novel BET Bromodomain Inhibitors Published in the Journal of Experimental Medicine

Results Demonstrate Therapeutic Benefit of BET Inhibition in Autoimmune Disease Models

CAMBRIDGE, Mass. – October 8, 2013Constellation Pharmaceuticals, Inc.

Read more »

next »